BE624526A - - Google Patents
Info
- Publication number
- BE624526A BE624526A BE624526DA BE624526A BE 624526 A BE624526 A BE 624526A BE 624526D A BE624526D A BE 624526DA BE 624526 A BE624526 A BE 624526A
- Authority
- BE
- Belgium
- Prior art keywords
- virus
- strain
- measles virus
- measles
- attenuation
- Prior art date
Links
- 241000712079 Measles morbillivirus Species 0.000 claims description 89
- 241000700605 Viruses Species 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 67
- 229960005486 vaccine Drugs 0.000 claims description 58
- 210000004027 cell Anatomy 0.000 claims description 38
- 230000008569 process Effects 0.000 claims description 31
- 239000001963 growth medium Substances 0.000 claims description 24
- 201000005505 Measles Diseases 0.000 claims description 23
- 238000011534 incubation Methods 0.000 claims description 23
- 230000006978 adaptation Effects 0.000 claims description 21
- 230000003053 immunization Effects 0.000 claims description 18
- 239000002609 medium Substances 0.000 claims description 14
- 230000002238 attenuated effect Effects 0.000 claims description 13
- 241000287828 Gallus gallus Species 0.000 claims description 11
- 241000282412 Homo Species 0.000 claims description 10
- 210000004102 animal cell Anatomy 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 210000001161 mammalian embryo Anatomy 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 230000007480 spreading Effects 0.000 claims description 6
- 238000003892 spreading Methods 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 241000271566 Aves Species 0.000 claims description 4
- 230000000116 mitigating effect Effects 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- PXXXZVXOMPUQRY-NKNAPQMISA-N OC(=O)[C@@H](N)CCC(O)=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical group OC(=O)[C@@H](N)CCC(O)=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O PXXXZVXOMPUQRY-NKNAPQMISA-N 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims 3
- 241001414890 Delia Species 0.000 claims 1
- 201000005866 Exanthema Subitum Diseases 0.000 claims 1
- 208000036485 Roseola Diseases 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 66
- 235000013330 chicken meat Nutrition 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000000120 cytopathologic effect Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 229940041323 measles vaccine Drugs 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229960003213 live attenuated measles Drugs 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000004135 animal tissue culture Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE624526A true BE624526A (show.php) |
Family
ID=196159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE624526D BE624526A (show.php) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE624526A (show.php) |
-
0
- BE BE624526D patent/BE624526A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2090721C (fr) | Procede de fecondation en cycle spontane | |
| FR2468372A1 (fr) | Nouveau vaccin contre les maladies infectieuses chez les bovins et son procede de production | |
| FR2801607A1 (fr) | Pneumovirus du canard et vaccins correspondants | |
| FR2962655A1 (fr) | Composition pharmaceutique d'association et ses utilisations dans les procedes de traitement des troubles du systeme genito-urinaire | |
| FR2602791A1 (fr) | Procede de culture du virus de la rhinotracheite infectieuse de la dinde, et vaccin prepare a partir du virus ainsi obtenu | |
| FR2590172A1 (fr) | Nouvel antigene commun (psc-a) de pseudomonas aeruginosa protegeant contre l'infection provoquee par cet organisme | |
| BE624526A (show.php) | ||
| FR2466251A1 (fr) | Vaccin animal anticolibacillaire, obtention et application | |
| EP0051522B1 (fr) | Mutant de septicémie hémorragique virale, vaccin contenant ce mutant et procédé pour sa préparation | |
| FR2538703A1 (fr) | Vaccin vivant pour la prevention de la salmonellose des oiseaux aquatiques et procede pour sa preparation | |
| CH412201A (fr) | Procédé de stabilisation d'un produit à base de virus antigène labile | |
| CH382917A (fr) | Procédé pour la production d'un virus-vaccin contre la maladie des chiens | |
| EP0106831B1 (fr) | Souches modifiées du virus de la diarrhée virale bovine, leur préparation et vaccins les contenant | |
| FR2479000A1 (fr) | Vaccin contre la brucellose, maladie du betail | |
| BE882619A (fr) | Vaccin pour le controle de la pleuropneumonie chez le porc | |
| BE554749A (show.php) | ||
| FR2607392A1 (fr) | Procede pour la preparation d'une souche mutante de bordetella bronchiseptica utile pour la preparation d'un vaccin vivant attenue pour la prophylaxie des infections a b. bronchiseptica et vaccin vivant attenue contre la rhinite atrophique ainsi prepare | |
| CH601479A5 (en) | Injectable Bordetella bronchiseptica vaccine | |
| US3468758A (en) | Measles vaccine attenuated through avian chorio-allantoic membrane | |
| CH320137A (fr) | Procédé de préparation d'un vaccin de virus de poliomyélite | |
| BE828941A (fr) | Vaccin et procede pour le preparer | |
| BE474490A (show.php) | ||
| FR2487201A2 (fr) | Preparation lymphocytaires applicables en therapeutique humaine, procede d'obtention et applications | |
| Delpy | Possibilities of improving anticholera vaccines and methods of evaluation of their efficacy | |
| WHO Expert Committee on Biological Standardization et al. | Comité OMS d'experts de la standardisation biologique [réuni à Genève du 28 novembre au 3 décembre 1966]: dix-neuvième rapport |